Search
Carbamoylcholine
go.drugbank.com/drugs/DB00411ApprovedCarbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932. Carbamoylcholine was initially used as a treatment for migraines, induction of diuresis, and other parasympathetic effects. Carbamoylcholine was grant...
Inotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalInotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It was FDA approved in October 2018. Inotersen has been shown to i...
NS-2359
go.drugbank.com/drugs/DB05805InvestigationalThis mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.
GTI 2040
go.drugbank.com/drugs/DB05801InvestigationalGTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
Atractylodes japonica root oil
go.drugbank.com/drugs/DB11270ApprovedWithdrawnIt is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.
Meningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
Methysergide
go.drugbank.com/drugs/DB00247ApprovedWithdrawnAn ergot derivative that is a congener of lysergic acid diethylamide.
Flavin adenine dinucleotide
go.drugbank.com/drugs/DB03147Approved(Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.
Bithionol
go.drugbank.com/drugs/DB04813ApprovedWithdrawnBithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders.
Dehydroascorbic acid
go.drugbank.com/drugs/DB08830ExperimentalCurrently dehydroascorbic acid is an experimental drug with no known approved indications. … This reaction is reversible, but dehydroascorbic acid can instead undergo irreversible hydrolysis to 2,3-diketogulonic acid.